About Corindus Vascular Robotics (NYSEAMERICAN:CVRS)
Corindus Vascular Robotics, Inc. is engaged in robotic-assisted vascular interventions. The Company's CorPath System is a medical device that brings robotic-assisted precision to radial, coronary and peripheral procedures. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System it brings robotic precision to radial and complex interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement with manual procedures. It operates through the development, marketing and sales of robotic-assisted vascular interventions segment. The CorPath System enables the robotic-assisted control of coronary guidewires and balloon/stent devices from the safety of a radiation-protected, ergonomic interventional cockpit. The CorPath System consists of two components: a bedside unit and an interventional cockpit.
Industry, Sector and Symbol:
- Industry: Advanced Medical Equipment & Technology
- Sub-Industry: N/A
- Sector: Advanced Medical Equipment & Technology - NEC
- Symbol: NYSEAMERICAN:CVRS
- Previous Symbol: NYSEMKT:CVRS
- CUSIP: N/A
- Web: www.corindus.com
- Trailing EPS: ($0.24)
- Net Margins: -372.63%
- Return on Equity: -94.27%
- Return on Assets: -75.51%
- Outstanding Shares: 188,700,000
Frequently Asked Questions for Corindus Vascular Robotics (NYSEAMERICAN:CVRS)
What is Corindus Vascular Robotics' stock symbol?
Corindus Vascular Robotics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CVRS."
How were Corindus Vascular Robotics' earnings last quarter?
Corindus Vascular Robotics Inc (NYSEAMERICAN:CVRS) posted its quarterly earnings results on Tuesday, November, 7th. The medical equipment provider reported ($0.04) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.05) by $0.01. The medical equipment provider earned $2.43 million during the quarter, compared to analyst estimates of $3.60 million. Corindus Vascular Robotics had a negative net margin of 372.63% and a negative return on equity of 94.27%. View Corindus Vascular Robotics' Earnings History.
Where is Corindus Vascular Robotics' stock going? Where will Corindus Vascular Robotics' stock price be in 2017?
2 equities research analysts have issued 1-year target prices for Corindus Vascular Robotics' stock. Their predictions range from $3.00 to $3.00. On average, they anticipate Corindus Vascular Robotics' share price to reach $3.00 in the next twelve months. View Analyst Ratings for Corindus Vascular Robotics.
Are investors shorting Corindus Vascular Robotics?
Corindus Vascular Robotics saw a increase in short interest in the month of October. As of October 31st, there was short interest totalling 10,628,907 shares, an increase of 0.2% from the October 13th total of 10,610,826 shares. Based on an average trading volume of 976,360 shares, the short-interest ratio is presently 10.9 days. Currently, 11.7% of the company's stock are sold short.
Who are some of Corindus Vascular Robotics' key competitors?
Some companies that are related to Corindus Vascular Robotics include GenMark Diagnostics (GNMK), Cytosorbents Corporation (CTSO), Cogentix Medical (CGNT), Alliance HealthCare Services (AIQ), Harvard Bioscience (HBIO), Viveve Medical (VIVE), IRIDEX Corporation (IRIX), Edap Tms S.A. (EDAP), Presbia PLC (LENS), Neovasc (NVCN), Fulgent Genetic (FLGT), Luna Innovations Incorporated (LUNA), Digirad Corporation (DRAD), Electromed (ELMD), InVivo Therapeutics Holdings Corp. (NVIV), Biolase (BIOL), Advanced Oncotherapy PLC (AVO) and EnteroMedics (RSLS).
Who are Corindus Vascular Robotics' key executives?
Corindus Vascular Robotics' management team includes the folowing people:
- Jeffrey C. Lightcap, Independent Chairman of the Board (Age 57)
- Mark J. Toland, President, Chief Executive Officer, Director (Age 46)
- David W. Long, Chief Financial Officer, Senior Vice President, Treasurer, Secretary (Age 46)
- John K. Bakewell, Director (Age 55)
- Louis A Cannon M.D., Director
- Gerard Winkels, Director (Age 59)
- Hillel Bachrach, Independent Director (Age 70)
- Jeffrey Gold, Independent Director (Age 68)
Who owns Corindus Vascular Robotics stock?
Corindus Vascular Robotics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Essex Investment Management Co. LLC (0.43%) and Schwab Charles Investment Management Inc. (0.20%). Company insiders that own Corindus Vascular Robotics stock include Healthcor Management, LP, Jeffrey Gold, Louis A Cannon and Philips Nv Koninklijke. View Institutional Ownership Trends for Corindus Vascular Robotics.
Who bought Corindus Vascular Robotics stock? Who is buying Corindus Vascular Robotics stock?
Corindus Vascular Robotics' stock was acquired by a variety of institutional investors in the last quarter, including Essex Investment Management Co. LLC and Schwab Charles Investment Management Inc.. Company insiders that have bought Corindus Vascular Robotics stock in the last two years include Healthcor Management, LP, Jeffrey Gold and Louis A Cannon. View Insider Buying and Selling for Corindus Vascular Robotics.
How do I buy Corindus Vascular Robotics stock?
Shares of Corindus Vascular Robotics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Corindus Vascular Robotics' stock price today?
One share of Corindus Vascular Robotics stock can currently be purchased for approximately $0.87.
How big of a company is Corindus Vascular Robotics?
Corindus Vascular Robotics has a market capitalization of $140.56 million.
How can I contact Corindus Vascular Robotics?
MarketBeat Community Rating for Corindus Vascular Robotics (NYSEAMERICAN CVRS)MarketBeat's community ratings are surveys of what our community members think about Corindus Vascular Robotics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Corindus Vascular Robotics' mailing address is 309 Waverley Oaks Rd Ste 105, WALTHAM, MA 02452-8451, United States. The medical equipment provider can be reached via phone at +1-508-6533335.
Analysts' Consensus Ratings for Corindus Vascular Robotics (NYSEAMERICAN:CVRS) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 2 Buy Ratings, 0 Strong Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$3.00|Consensus Price Target History for Corindus Vascular Robotics (NYSEAMERICAN:CVRS)
Analysts' Ratings History for Corindus Vascular Robotics (NYSEAMERICAN:CVRS)
(Data available from 11/17/2015 forward)
|8/9/2017||Cowen and Company||Set Price Target||Buy||$3.00|
|5/15/2017||B. Riley||Reiterated Rating||Buy||$3.00|
|4/20/2016||Sterne Agee CRT||Reiterated Rating||Buy||$3.00|
|1/19/2016||Stifel Nicolaus||Lower Price Target||Buy||$6.00 -> $4.00|
Earnings History for Corindus Vascular Robotics (NYSEAMERICAN:CVRS)Earnings History by Quarter for Corindus Vascular Robotics (NYSEAMERICAN CVRS)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/7/2017||Q3 2017||($0.05)||($0.04)||$3.60 million||$2.43 million||View||N/A|
|8/8/2017||Q2 2017||($0.05)||($0.04)||$3.10 million||$2.26 million||View||Listen|
|5/9/2017||Q1 2017||($0.05)||($0.07)||$1.59 million||$0.78 million||View||Listen|
|3/15/2017||Q4 2016||($0.07)||($0.08)||$0.73 million||$0.54 million||View||N/A|
|11/8/2016||Q316||($0.06)||($0.07)||$1.27 million||$0.69 million||View||Listen|
|3/8/2016||Q415||($0.05)||($0.06)||$0.62 million||$0.83 million||View||N/A|
|11/12/2015||Q315||($0.06)||($0.06)||$0.70 million||$0.21 million||View||Listen|
Earnings Estimates for Corindus Vascular Robotics (NYSEAMERICAN:CVRS)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Corindus Vascular Robotics (NYSEAMERICAN:CVRS)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Corindus Vascular Robotics (NYSEAMERICAN CVRS)Insider Trades by Quarter for Corindus Vascular Robotics (NYSEAMERICAN CVRS)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|11/13/2017||Louis A Cannon||Director||Buy||23,801||$0.81||$19,278.81|| |
|3/22/2017||Louis A Cannon||Director||Buy||27,000||$1.30||$35,100.00|| |
|2/28/2017||Healthcor Management, L.P.||Major Shareholder||Buy||7,557,436||$0.66||$4,987,907.76|| |
|11/25/2016||Jeffrey Gold||Director||Buy||10,000||$0.76||$7,600.00|| |
Headline Trends for Corindus Vascular Robotics (NYSEAMERICAN:CVRS)
Latest Headlines for Corindus Vascular Robotics (NYSEAMERICAN CVRS)
No headlines for this company have been tracked by MarketBeat.com
Corindus Vascular Robotics (NYSEAMERICAN CVRS) Chart for Friday, November, 17, 2017